Nyxoah SA (NASDAQ:NYXH) Short Interest Update

Nyxoah SA (NASDAQ:NYXH) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 826,117 shares, a growth of 185.5% from the May 31st total of 289,376 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 965,701 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Upgrades and Downgrades

Several research firms have commented on NYXH. Stifel Nicolaus cut their price objective on Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, June 17th. Piper Sandler restated an “overweight” rating and issued a $7.00 target price (down from $9.00) on shares of Nyxoah in a research report on Wednesday, May 13th. Weiss Ratings lowered Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of Nyxoah in a research report on Monday, March 23rd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Nyxoah currently has an average rating of “Hold” and an average price target of $7.00.

Institutional Investors Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Nyxoah in the 2nd quarter valued at approximately $70,000. Citadel Advisors LLC purchased a new stake in shares of Nyxoah during the 3rd quarter valued at approximately $98,000. Deutsche Bank AG raised its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after buying an additional 10,000 shares during the period. Finally, Shay Capital LLC purchased a new stake in shares of Nyxoah during the 2nd quarter valued at approximately $374,000.

Nyxoah Trading Down 0.6%

Nyxoah stock traded down $0.01 during trading on Tuesday, reaching $1.64. 44,744 shares of the company were exchanged, compared to its average volume of 157,036. The stock’s 50 day simple moving average is $2.50 and its two-hundred day simple moving average is $3.60. The company has a market capitalization of $63.57 million, a P/E ratio of -0.66 and a beta of 1.55. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.99 and a quick ratio of 0.88. Nyxoah has a 52-week low of $1.26 and a 52-week high of $8.59.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Tuesday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.11. Nyxoah had a negative return on equity of 163.73% and a negative net margin of 543.21%.The company had revenue of $7.38 million during the quarter, compared to analysts’ expectations of $7.05 million. On average, equities research analysts expect that Nyxoah will post -1.67 earnings per share for the current fiscal year.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep?disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.